HormonalIn Clinical TrialsClinical Trials

Kisspeptin

Also known as Kisspeptin-10, Kisspeptin-54, Metastin

A neuropeptide that plays a critical role in initiating puberty and regulating the reproductive hormone axis.

Investigational - Clinical trials ongoing

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

100-200 mcg subcutaneously once daily

Frequency

Once daily or every other day

Duration

Variable by protocol

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 100-200 mcg subcutaneously once daily via Subcutaneous injection (investigational); IV (research), Once daily or every other day. Dose range: 50-500 mcg per day. Duration: Variable by protocol.

Timing & Administration

Administer via Subcutaneous injection (investigational); IV (research). Frequency: Once daily or every other day.

Mechanism of Action

Binds to KISS1R receptors in the hypothalamus, triggering GnRH release and initiating hormonal cascades that regulate testosterone and estrogen production.

Research Summary

Evidence level: clinical trials. Clinical status: Investigational - Clinical trials ongoing.

Side Effects & Safety

Important Warnings

  • Long-term hormonal effects unknown
Generally well-tolerated
temporary flushing
mild headache
nausea

References

No references available.